Kincell Bio, a CDMO focused on producing cell therapies, signed an unnamed client to a multi-year deal to manufacture personalized, clinical-grade regenerative treatments.
The partnership is slated to add work at Kincell's site in Gainesville, Florida, the company said in a Sept. 16 press release. The client was described by Kincell as a clinical-stage cell therapy company investigating regenerative medicines for a variety of “critical” indications.
Financial details of the deal weren’t disclosed.
“We’re delighted to welcome another client to our Gainesville facility,” Bruce Thompson, Kincell’s chief executive, said in the release. “Our facility is GMP-ready, and our team thrives on providing critical CMC development and manufacturing expertise to support our clients’ clinical development plans to help patients.”
Back in April, Kinsell said it would shell out $6 million over the next three years and kick in milestone-driven payments to take over immuno-oncology biotech Imogene’s North Carolina cell manufacturing facility and hire the site’s associated staffers.
Under that deal, Kincell picked up a new 32,800-square-foot site in Research Triangle Park. Imugene, for its part, aimed to save $32 million through staff cost cuts, manufacturing efficiencies and overhead savings.